How Real-World Data Helps Explore Alternative Dosing for Colorectal, Pancreatic Cancer Therapy
Research from MedStar Georgetown Lombardi Comprehensive Cancer Center and COTA shows the potential of a more patient-friendly dosing regimen for Stage 4 CRC/PC or locally advanced PC.
This collaboration highlights how real-world data can contribute to clinical research and can help answer pressing questions about care already taking place in clinical practice.
Key Takeaways from ASH 2022: Real-World Data Gets Down to Business
The American Society of Hematology’s 2021 annual meeting showed that real-world data is no longer the new kid on the block – it’s an indispensable part of the toolkit for therapeutic development and clinical research. COTA is proud to be a part of the discussion, contributing research this year for chronic lymphocytic leukemia.
Are Pharma Companies Ready to Harness the Promises of Real-World Data?
Partnering with Impatient Health, we take a comprehensive look at the realities of real-world data and the challenges that pharma companies face in leveraging it to gain actionable insight, based on feedback from executives at well-known, major pharma companies.
This is a key part of our mission to provide the most comprehensive cancer care possible by leveraging the latest advances in data science and technology.
